BioNTech, the prominent developer of mRNA vaccines, has released preliminary results for its BNT211 vaccine, which combines two techniques: cell therapy using CAR-T cells to target the CLDN6 antigen found in various types of cancer cells, and CARVac, a vaccine that prolongs the duration of cancer cell targeting for their elimination from the body. The overall response rate (ORR) was found to be 59%, with a disease control rate (DCR) of 95%.
In the phase 1/2 trial, both safety and efficacy were assessed concurrently, with a relatively small sample size of 44 patients. These patients included 16 cases of solid tumor, 17 cases of ovarian cancer, and 11 cases of other solid tumors. The safety report indicated increased side effects with higher dosage administration.
These trial results were presented at the ESMO conference in 2023, alongside the development of four other experimental drugs by BioNTech, such as BNT116 for lung cancer treatment. Moving forward, BioNTech plans to conduct phase 2 trials for BNT211 in 2024.
TLDR: BioNTech, a leading developer of mRNA vaccines, announces early results for its BNT211 vaccine, a combination of cell therapy using CAR-T cells and a vaccine called CARVac. The vaccine demonstrates an overall response rate of 59% and a disease control rate of 95%. The phase 1/2 trial indicates increased side effects with higher doses. Further trials are planned for the BNT211 vaccine in 2024.